The gold standard of care for hepatocellular carcinoma patients with intermediate- to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. NCI scientists have identified a 14-gene signature predictive of response to TACE, and NCI seeks licensees or co-development partners to develop the technology toward commercialization.
The National Cancer Institute (NCI) seeks licensees for a monoclonal antibody specific to the GalNAc1-3Gal antigen that is present in human carcinomas. The antibody can be used as a research tool for a variety of purposes, including immunohistochemical staining of various human carcinomas. The antibody may also be useful as a prognostic marker for cervical cancer.
Scientists at the National Cancer Institute have developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The National Cancer Institute seeks parties to non-exclusively license this research material.
Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit activity of hypoxia inducible factor 1 (HIF-1). The HIF-1 inhibitor compounds are designed around the scaffold of naturally occurring metabolite eudistidine. The invention compounds have demonstrated activity against cancer and malaria in vitro.
Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).
Researchers at the National Institutes for Health Clinical Center (NIHCC) have developed computer-aided diagnostics (CAD) that may further improve the already superior capabilities of multiparametric magnetic resonance imaging (MRI) for detection and imaging of prostate cancer. This system produces an accurate probability map of potential cancerous lesions in multiparametric MRI images that is superior to other systems and may have multiple product applications.
Researchers at NCI have developed a means of more closely simulating in mouse models both melanoma cancer itself and the resulting physiological an immunological response by creating a genetically engineered mice (GEM)-derived allograft (GDA). This allograft both resembles human-like melanoma and has features that will stimulate a normal immunological response in the mouse.
There are currently no methodologies that allow for epigenome, genome and transcriptome analysis all in a single cell. In addition, there are currently no methodologies that permit repeating the results of these analyses on the same single cells.
Scientists at the National Cancer Institute (NCI) Laboratory of Cellular Oncology have developed a method for generating a “reusable” single cell that allows for repeated experiments on the same cell. Utilizing this methodology epigenomic, genomic, and transcriptomic analysis can be performed on the same cell. NCI seeks parties to license or co-develop the technology through research collaborations.
Novel Furoquinolinediones derivatives may act as an anti-cancer agent by the inhibition of tyrosyl-DNA phosphodiesterase 2 (TDP2), an enzyme involved in DNA repair and transcription factor activation. These Furoquinolinediones derivatives may also be used in combination therapies to effectively kill cancer cells.
The National Cancer Institute's Medical Oncology Branch is seeking statements of capability or interest from parties interested in licensing and co-development collaborative research to further develop, evaluate, or commercialize novel kinase inhibitors targeting the PH domain of AKT.
The National Cancer Institute seeks licensees and/or co-development partners for methods that provide significant improvements in examining clinically relevant tissue samples, by improving spatial resolution and tissue depth using optical trapping.
Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.
Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of California, Santa Barbara (UCSB), developed a tetrahedral-shaped RNA nanoparticle for the delivery of siRNA to activate RNAi. The tetrahedral RNA nanoparticles can contain twelve Dicer substrate RNA duplexes for gene silencing. The NCI seeks parties interested in co-development or licensing of these tetrahedral RNA nanoparticles.
The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy.
The National Institute of Child Health and Human Development (NICHD), Division of Intramural Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical samples with genetic mutations associated with endocrine tumors.